This grant is for establishing Clinical Centers as part of the NHLBI Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) program. The primary purpose is to assemble a multidisciplinary team to conduct state-of-the-art genomic, microbiomic, and phenotypic studies on Alpha-1 Antitrypsin Deficiency (AAT) and sarcoidosis, two serious lung conditions. Selected Clinical Centers will participate in a study-wide protocol, enrolling, clinically phenotyping, and collecting biospecimens from approximately 400 AAT and 200 sarcoidosis subjects and controls. Additionally, each center will develop a clinic-specific research protocol to identify pathogenetic mechanisms or predictors of disease development/progression. This collaborative effort will advance understanding of these understudied conditions.
Opportunity ID: 67773
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-HL-12-013 |
| Funding Opportunity Title: | Genomic Research in AAT-Deficiency and Sarcoidosis study (GRADS) Cooperative Research Project Grant: Clinical Centers (U01) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.838 — Lung Diseases Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Feb 02, 2011 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | May 17, 2011 |
| Current Closing Date for Applications: | May 17, 2011 |
| Archive Date: | Jun 17, 2011 |
| Estimated Total Program Funding: | $12,000,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Independent school districts Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Private institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) Native American tribal governments (Federally recognized) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Small businesses State governments County governments Public and State controlled institutions of higher education City or township governments Special district governments |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The purpose of this funding opportunity announcement (FOA), issued by NHLBI, NIH, is to invite applications to participate in the NHLBI Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) program, which will assemble a multidisciplinary team of investigators to conduct state-of-art genomic, microbiomics and phenotypic studies of two serious and understudied conditions that affect the lungs: Alpha-1 Antitrypsin Deficiency (AAT) and sarcoidosis. GRADS will include up to eight Clinical Centers and one Genomics and Informatics Center (GIC). This FOA solicits applications for Clinical Centers and runs in parallel with a separate FOA that solicits applications for the GIC (see RFA-HL-12-014). The GRADS Clinical Centers will participate in a study-wide protocol by enrolling, clinically and immunologically phenotyping participants, and collecting and processing biospecimens to be shipped to the GIC for genomics and microbiomics analyses. Additionally, each Clinical Center will develop a clinic-specific research protocol aimed at identifying pathogenetic mechanisms or predictors of AAT or sarcoidosis disease development/progression. Collectively the GRADS Clinical Centers will create a program-wide cohort of approximately 400 AAT and approximately 200 sarcoidosis subjects and controls. Up to 8 Clinical Centers will be funded, each led by one or more Investigators with expertise in AAT, sarcoidosis, pulmonary medicine, immunology, genomics or cell biology. A Steering Committee of all the Clinical Center Principal Investigators will be organized by the GIC (see RFA-HL-12-014) to develop the study-wide protocol(s) and monitor study operations. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-12-013.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
There are no packages on this grant.
Share This Post, Choose Your Platform!
About the Author: osnqt
